These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8847295)

  • 1. Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects.
    Widness JA; Veng-Pedersen P; Peters C; Pereira LM; Schmidt RL; Lowe LS
    J Appl Physiol (1985); 1996 Jan; 80(1):140-8. PubMed ID: 8847295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Mechanism-Based Population Pharmacokinetics Model of Erythropoietin in Premature Infants and Healthy Adults Following Multiple Intravenous Doses.
    D'Cunha R; Widness JA; Yan X; Schmidt RL; Veng-Pedersen P; An G
    J Clin Pharmacol; 2019 Jun; 59(6):835-846. PubMed ID: 30618050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early treatment of premature infants with recombinant human erythropoietin.
    Messer J; Haddad J; Donato L; Astruc D; Matis J
    Pediatrics; 1993 Oct; 92(4):519-23. PubMed ID: 8414820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-versus low-dose erythropoietin in extremely low birth weight infants. The European Multicenter rhEPO Study Group.
    Maier RF; Obladen M; Kattner E; Natzschka J; Messer J; Regazzoni BM; Speer CP; Fellman V; Grauel EL; Groneck P; Wagner M; Moriette G; Salle BL; Verellen G; Scigalla P
    J Pediatr; 1998 May; 132(5):866-70. PubMed ID: 9602202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythrocyte incorporation and absorption of 58Fe in premature infants treated with erythropoietin.
    Widness JA; Lombard KA; Ziegler EE; Serfass RE; Carlson SJ; Johnson KJ; Miller JE
    Pediatr Res; 1997 Mar; 41(3):416-23. PubMed ID: 9078545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythrocyte iron incorporation but not absorption is increased by intravenous iron administration in erythropoietin-treated premature infants.
    Widness JA; Serfass RE; Haiden N; Nelson SE; Lombard KA; Pollak A
    J Nutr; 2006 Jul; 136(7):1868-73. PubMed ID: 16772451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenous and subcutaneous administration.
    Brown MS; Jones MA; Ohls RK; Christensen RD
    J Pediatr; 1993 Apr; 122(4):655-7. PubMed ID: 8463922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron absorption and oxidant stress during erythropoietin therapy in very low birth weight premature infants: a cohort study.
    Friel JK; Aziz K; Andrews WL; Serfass RE
    BMC Pediatr; 2005 Aug; 5():29. PubMed ID: 16080798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron.
    Ohls RK; Ehrenkranz RA; Das A; Dusick AM; Yolton K; Romano E; Delaney-Black V; Papile LA; Simon NP; Steichen JJ; Lee KG;
    Pediatrics; 2004 Nov; 114(5):1287-91. PubMed ID: 15520109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution.
    Ohls RK; Veerman MW; Christensen RD
    J Pediatr; 1996 Apr; 128(4):518-23. PubMed ID: 8618186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g.
    Maier RF; Obladen M; Müller-Hansen I; Kattner E; Merz U; Arlettaz R; Groneck P; Hammer H; Kössel H; Verellen G; Stock GJ; Lacaze-Masmonteil T; Claris O; Wagner M; Matis J; Gilberg F;
    J Pediatr; 2002 Jul; 141(1):8-15. PubMed ID: 12091844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial.
    Natalucci G; Latal B; Koller B; Rüegger C; Sick B; Held L; Bucher HU; Fauchère JC;
    JAMA; 2016 May; 315(19):2079-85. PubMed ID: 27187300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption of enteral recombinant human erythropoietin by neonates.
    Juul SE; Christensen RD
    Ann Pharmacother; 2003 Jun; 37(6):782-6. PubMed ID: 12773061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietin: possible role as an antioxidant in premature rabbits.
    Bany-Mohammed FM; Slivka S; Hallman M
    Pediatr Res; 1996 Sep; 40(3):381-7. PubMed ID: 8865272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recombinant human erythropoietin in premature infants. Evaluation of a one year experience].
    Trentesaux AS; Egreteau L; Santerne B; Morville P
    Arch Pediatr; 1999 Sep; 6(9):944-51. PubMed ID: 10519027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors related to transfusion in very low birthweight infants treated with erythropoietin.
    Maier RF; Obladen M; Messinger D; Wardrop CA
    Arch Dis Child Fetal Neonatal Ed; 1996 May; 74(3):F182-6. PubMed ID: 8777681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a restricted transfusion schedule with erythropoietin therapy versus a restricted transfusion schedule alone in very low birth weight premature infants.
    Birenbaum HJ; Pane MA; Helou SM; Starr KP
    South Med J; 2006 Oct; 99(10):1059-62. PubMed ID: 17100024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP.
    Jelkmann W
    Eur J Haematol; 2002; 69(5-6):265-74. PubMed ID: 12460230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Erythropoietin and anemia in premature infants].
    Saizou C; Moriette G; Sauchez L
    Arch Pediatr; 2004 Dec; 11(12):1516-20. PubMed ID: 15596348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics.
    Chapel SH; Veng-Pedersen P; Schmidt RL; Widness JA
    Exp Hematol; 2001 Apr; 29(4):425-31. PubMed ID: 11301182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.